18:48 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver fibrosis Patient sample and mouse studies suggest antagonizing AHR or RORγT could help treat liver fibrosis. In liver tissue samples from hepatitis patients, levels of IL-17A and IL-22, which are positively regulated by...
15:43 , Sep 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Patient sample, cell culture and mouse studies suggest antagonizing AHR could help treat MM. In patients, high tumor levels of AHR correlated with poor survival. In multiple Velcade bortezomib-resistant and -sensitive...
18:58 , Aug 31, 2018 |  BC Week In Review  |  Company News

Dermavant, NovaQuest in milestone deal for tapinarof

The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) received the $100 million investment from NovaQuest Capital Management in exchange for milestone payments related to tapinarof. The aryl hydrocarbon receptor (AHR) modulator has...
20:44 , Aug 28, 2018 |  BC Extra  |  Company News

Roivant units Urovant, Dermavant in deals as NEA’s Torti joins ‘vant’ team

Two Roivant Sciences GmbH (Basel, Switzerland) subsidiaries struck deals on Tuesday, with Urovant Sciences gaining rights to a gene therapy for overactive bladder and Dermavant Sciences receiving a $100 million investment tied to its tapinarof....
23:46 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Metabolic syndrome Patient sample and mouse studies suggest AHR agonists could help treat metabolic syndrome. In patient fecal samples, levels of endogenous AHR ligands -- including indole, indole acetic acid, 3-methylindole and tryptamine --...
23:54 , Apr 26, 2018 |  BC Innovations  |  Targets & Mechanisms

Raising metabolism

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt,...
16:58 , Mar 16, 2018 |  BC Week In Review  |  Financial News

Synthetic lethality company Ideaya raises $94M

Ideaya Biosciences Inc. (South San Francisco, Calif.) raised $94 million in a series B round on March 15 led by Nextech Invest, 6 Dimensions Capital, BVF Partners and Perceptive Advisors. Fellow new investors GV, Roche...
00:20 , Mar 16, 2018 |  BioCentury  |  Finance

Following its blueprint

Ideaya Biosciences Inc.’s goal of developing treatments for genomically defined subsets of cancer patients led Nextech Invest to co-lead the company’s $94 million series B round. Nextech, 6 Dimensions Capital, BVF Partners and Perceptive Advisors...
11:55 , Mar 15, 2018 |  BC Extra  |  Financial News

Synthetic lethality company Ideaya raises $94M

Ideaya Biosciences Inc. (South San Francisco, Calif.) raised $94 million in a series B round led by Nextech Invest, 6 Dimensions Capital, BVF Partners and Perceptive Advisors. Fellow new investors GV, Roche Venture Fund, Boxer...
21:28 , Dec 15, 2017 |  BioCentury  |  Finance

Kyndred spirits

Partners Kyn Therapeutics Inc. and Arrys Therapeutics Inc. share an...